News & Analysis on Clinical Trial Services & Contract Research And Development
Norwegian biotechnology firm, Genpoint, is running trials of new DNA tests for tuberculosis (TB) in which its novel DNA method aims to cut diagnosis time, cheaper and quicker without an increase of personnel in the health care sector.
Scientists have synthesised a lab-made version of a human protein, which alleviates symptoms of both acute and chronic arthritis. The study opens new research avenues to better understand and develop drug treatments for rheumatoid arthritis.
Tecan, supplier of compound and sample storage, releases the new HS Pro series of automated microarray hybridisation stations, which providing fully automated slide processing, from pre-hybridisation to automated slide drying.
Australian drug delivery company pSivida has inked a deal valued at $104 million (€87m) to buy Control Delivery Systems of the US, allowing it tap into the biotechnology hub around Boston on the US east coast.
Researchers in France have developed a new microporous material that could have a range of applications for the pharmaceutical industry, including chemical separation and catalysis in medicine manufacturing and drug delivery.
The production capacity for biopharmaceutical manufacturing will expand an average of 48 per cent over the next five years for mammalian and microbial production systems, according to an industry survey.
Elusys Therapeutics' Anthrax drug candidate is to commence human clinical trials after the biopharmaceutical company received Institutional Review Board (IRB) approval. The drug, which has already received "Fast Track" approval, is expected to begin...
According to a new report, growing regulations in the European pharmaceuticals industry is having a harmful effect on the market, causing many companies to shift their bases to the United States where the directives are more relaxed.
Avecia spin-out Reaxa has launched a new peptide coupling technology based on 2-mercaptobenzothiazole (2-MBT), which it claims offers major operational and cost benefits in both small and large scale solid-phase peptide synthesis.
MerLion Pharmaceuticals has entered into a collaborative agreement with Astellas Pharma to identify new anti-cancer drug candidates derived from natural product chemistry.